Michelle Longmire, Medable CEO (Jeff Rumans)
November 24, 2020 11:14 AM EST
Financing

Med­able gets $91M for vir­tu­al clin­i­cal tri­als, bring­ing to­tal raise to $136M

Nicole DeFeudis

Editor

As biotechs look to get clin­i­cal stud­ies back on track amid the pan­dem­ic, Med­able re­turned to the ven­ture well for the sec­ond time this year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

A service from the Financial Times